Junik Junior (Beclometasone Dipropionate)

Beclometasone dipropionate binds to glucocorticoid receptors in airway cells, altering gene expression to suppress inflammatory cytokines, reduce eosinophil activity, and limit mucus production, which together lower airway inflammation and hyper‑responsiveness.

The prescribed dose of Junik Junior is individualized by a healthcare professional based on the patient’s age, disease severity, and response to therapy. Patients should follow the dosing instructions provided by their prescriber.

Safety data for beclometasone dipropionate in pregnancy and lactation are limited. The prescriber should weigh potential benefits against risks and discuss any concerns with the patient before initiating therapy.

To request Junik Junior, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Junik Junior contains beclometasone dipropionate, a medium‑potency inhaled corticosteroid. Compared with higher‑potency agents such as fluticasone or budesonide, it may require higher daily doses for equivalent anti‑inflammatory effect, but it is well‑studied for both asthma and COPD maintenance therapy.

Store Junik Junior at room temperature, below 25 °C, in the original packaging. Keep the device away from moisture and direct sunlight to maintain product stability.

Junik Junior is delivered via inhalation using a metered‑dose inhaler. The patient should exhale fully, place the mouthpiece in the mouth, inhale slowly while actuating the device, then hold the breath for several seconds before exhaling.

Serious risks include adrenal suppression, pneumonia, cataracts or glaucoma, severe allergic reactions, and growth suppression in children. Patients should be monitored regularly for these potential effects, especially with high‑dose or long‑term use.

Junik Junior should be avoided in patients with known hypersensitivity to beclometasone dipropionate or any inhaler excipients. Caution is also advised for individuals with active untreated infections or uncontrolled systemic fungal diseases.